755: A gemcitabine prodrug for the treatment of castration-resistant prostate cancer: Reduced metabolic inactivation combined with targeted drug delivery

Authors :: Andreas G. Tzakos
Constantin Tamvakopoulos
Orestis Argyros
Theodoros Karampelas
Nisar Sayyad
Demosthenes Fokas
Source :: European Journal of Cancer. 50:S182
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Castration resistant
Prodrug
medicine.disease
Gemcitabine
Prostate cancer
Metabolic Inactivation
Targeted drug delivery
Internal medicine
Cancer research
Medicine
business
medicine.drug

Tools